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Abstract
Drug-resistant infections caused by bacteria with increasing antimicrobial
resistance (AMR) threaten our ability to treat life-threatening conditions.
Tackling AMR requires international collaboration and partnership. An early and
leading priority to do this is to strengthen AMR surveillance, particularly in
low-income countries where the burden of infectious diseases is highest and
where data are most limited.
The World Health Organization (WHO) has developed the Global AMR
Surveillance System (GLASS) as one of a number of measures designed to
tackle the problem of AMR, and WHO member states have been encouraged
to produce National Action Plans for AMR by 2017. However, low-income
countries are unlikely to have the resources or capacity to implement all the
components in the GLASS manual. To facilitate their efforts, we developed a
guideline that is aligned to the GLASS procedures, but written specifically for
implementation in low-income countries. The guideline allows for flexibility
across different systems, but has sufficient standardisation of core protocols to
ensure that, if followed, data will be valid and comparable. This will ensure that
the surveillance programme can provide health intelligence data to inform
evidence-based interventions at local, national and international levels.
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Introduction
Antimicrobial resistance (AMR) develops when strains of 
micro-organisms evolve to survive exposure to antimicrobial 
agents. The subsequent transmission and spread of resistant path-
ogenic bacteria sets the scene for development of drug-resistant 
infections (DRIs). The increasing use of antimicrobials world-
wide has been associated with a global increase in DRIs, which 
threatens to return clinical therapies to the pre-antibiotic era. At 
present, DRIs are estimated to account for 50,000 deaths each year 
in Europe and the USA alone1, but by 2050 it is estimated that 
DRIs will account for 10 million deaths per year worldwide, posing 
an economic and biosecurity threat2.
Countries with the highest burdens of communicable diseases 
usually have the least resources and, in these settings, data on 
AMR and DRIs are most limited3,4. While large regional AMR 
surveillance networks have been established in Europe (EARS-
Net), Latin America (Red Latinoamericana de Vigilancia de la 
Resistencia a los Antimicrobianos, ReLAVRA) and Central Asia 
and Eastern Europe (CAESAR), capacity for AMR surveillance in 
low-income countries is relatively limited and fragmented, despite 
evidence that, as with the rest of the world, AMR in low-income 
regions is increasing3.
The importance of strengthening AMR surveillance in low- 
income countries was highlighted in 2014 by a United Kingdom 
government-commissioned review1. In response, the United 
Kingdom Department of Health launched the Fleming Fund to 
support low-income countries in developing AMR surveillance 
systems. The fund is aligned with the World Health Organiza-
tion (WHO)’s Global AMR Surveillance System (GLASS)5 to 
support the Global Action Plan on AMR3. The aims of the WHO 
AMR surveillance programme include monitoring trends in 
infection and resistance to develop standard treatment guide-
lines that support best practice for patient care, but also recognise 
the importance of linking information on AMR from different 
sectors, such as human, animal, food, agriculture, environment, 
and data on antibiotic use in human and animal populations and 
environmental antibiotic usage. AMR surveillance should also 
allow for assessment of interventions to reduce AMR, provide 
early alerts for emergence of novel resistant strains, and aid the 
rapid identification and control of outbreaks6. 
Recognising that AMR surveillance capacity varies considerably, 
to facilitate AMR surveillance and participation in GLASS for 
low-income countries, we aimed to identify an approach to allow 
independent development of each component of surveillance 
to build a comprehensive system. This result is a full guideline 
(Supplementary File 1) that has been developed with the objec-
tive of supporting capacity development in a standardised manner 
while allowing flexibility to incorporate country or regional 
priorities. The guideline is intended to:
•    be suitable for use by low-income countries, recognising the 
context of different health systems;
•    be based on an assessment of available evidence and review 
of established protocols in comparable resource settings;
•    provide a basis for early collection and analysis of data on 
AMR that will help countries to assess the extent of AMR in 
important pathogens and participate in global and regional 
surveillance (GLASS);
•    take into account the need for epidemiological and statistical 
validity and quality assurance, so that the data can be 
used, shared and combined to provide reliable evidence of 
AMR prevalence and to evaluate the effectiveness of 
interventions;
•    provide a tiered structure, with a minimum level of essential 
(core) activities and scope for expansion so that countries 
can select the level of operation to suit their circumstances, 
with the ability to expand and broaden to advanced surveil-
lance activities over time;
•    provide a roadmap for improving laboratory capacity, data 
collection and surveillance for AMR with an effective One 
Health approach, through multi-sectoral involvement across 
the interface between humans, animals and their various 
environments.
While recognising the global importance of drug resistance 
among viruses, fungi and parasites, this document focuses on 
bacterial infections in humans, and particularly on eight patho-
gens identified by the WHO as priority organisms for the early 
implementation of AMR surveillance. However, we anticipate 
that activities that improve the isolation, identification, suscepti-
bility testing and reporting of these organisms will support devel-
opment of clinical diagnostics for other pathogens, and can be 
tailored in-country for locally important or emergent bacteria.
Similarly, while the emphasis in this guideline is on human 
clinical pathogens, we recommend, in line with WHO, that AMR 
surveillance, in the long term, be embedded in a One Health 
approach. To support this, there should be multi-sector represen-
tation (including involvement from agriculture and veterinary 
medicine) in AMR surveillance bodies from the outset, in order to 
inform, monitor and control the threat to public health arising from 
AMR.
Methods
We brought together a team with expertise in microbiology, 
genomics, epidemiology, public health, infectious diseases and 
experience in setting up surveillance systems in low income 
countries. We reviewed the existing published and grey litera-
ture on infectious disease surveillance networks, including the 
Global Antibiotic Resistance Partnership (GARP), European 
Antimicrobial Resistance Surveillance Network (EARS-Net), 
Latin American Antimicrobial Resistance Surveillance Network 
(ReLAVRA), Central Asian and Eastern European Surveillance 
of Antimicrobial Resistance (CAESAR), and the Worldwide 
Antimalarial Resistance Network (WARN). These were critically 
assessed according to the context they were designed for, and 
their relevance to AMR surveillance in low and middle income 
countries. Concurrently, we reviewed AMR surveillance systems 
and existing AMR surveillance capacity7.
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Based on these data, and aligned to the Global Antimicrobial 
Surveillance System (GLASS), we drafted proposals for a 
roadmap for participation in GLASS. We shared these with experts 
and stakeholders in a two-day meeting in London, United Kingdom 
(July 2016). The meeting included representatives from the WHO, 
The Wellcome Trust, the Bill & Melinda Gates Foundation, 
Public Health England, and representatives of relevant networks 
such as the Central Asian and Eastern European Surveillance of 
Antimicrobial Resistance (CAESAR). We included expertise and 
representation from a range of key geographies in sub-Saharan 
Africa and South Asia. Following this, we revised our proposals, 
and recirculated for final review. The full guideline is included as 
Supplementary File 1 to this article.
Results
AMR Surveillance system
We recommend a sentinel surveillance system8, with step-wise 
expansion to increase the numbers of participating sites and their 
scope. In the first instance, we propose that countries should 
identify or develop capacity in a single site that can undertake 
surveillance to an acceptable core standard. Having achieved that 
standard, the primary site should support the development of good 
practice in secondary sites, with the long-term aim of building a 
comprehensive network of sentinel sites which can provide high-
quality representative AMR data. Sentinel sites that have achieved 
core capacity may aspire to higher standards (extended and 
advanced, Supplementary File 1: Appendix D) by developing and 
extending their capabilities.
Legal and ethical considerations
Public health surveillance is usually legally mandated by the 
national government. For public health surveillance programmes, 
the probability and the magnitude of harm to the population aris-
ing from not reporting surveillance data must be moderate to major 
to justify the use of individual patient data without individual 
patient consent9. In this context, the WHO has recently recognised 
AMR as a significant potential global health threat10. Reporting 
the characteristics of resistant pathogens rarely represents a threat 
to patient confidentiality, but the inclusion of simple clinical data 
such as age, sex, collection date, specimen type and syndromic 
diagnosis adds considerable value to the information obtained 
from the laboratory, and there are clear benefits from AMR sur-
veillance at patient, pathogen and population levels6. Examples of 
the application of AMR data include timely feedback to clinicians 
to support patient care and enable rationalisation of antibiotic 
treatment; use of data to inform local antimicrobial prescribing 
guidelines and infection control policies; analysis of clinical 
surveillance data (at international, national and / or local level) to 
enable public health interventions; cross-policy collaboration and 
support for research institutions to analyse clinical surveillance 
data, adopting a One Health to understand the emergence, 
transmission and dissemination of pathogens at the human-animal 
interface.
Given the need to integrate data from different sources, including 
individual patient data, it is essential that there are data 
governance agreements and procedures in place. These should 
protect the confidentiality of individual patients, but also facilitate 
the sharing of AMR surveillance data to inform policy locally, 
nationally and internationally. To meet ethical obligations, tech-
nical, legal and/or political barriers to data sharing11 must be 
overcome, and best practice for data collection ensured. For these 
reasons, a successful AMR surveillance programme requires clear 
political support, and should engage accordingly with the relevant 
government bodies11.
National Action Plan
The first step in establishing AMR surveillance is the development 
of a National Action Plan (NAP) for AMR, as set out by the 
WHO Global Action Plan on AMR3. WHO member states 
have been encouraged to develop NAPs and a manual and 
template are available to support this process (http://www.who.int/ 
drugresistance/action-plans/manual/en/).
Governance and structures
Each country should develop its own organisational structures 
(Figure 1), and define terms of reference. While the governance 
structure may vary, important factors include identification of a 
National Coordinating Centre (NCC), convening a technical team, 
and strong engagement with the Ministry of Health, reflecting the 
national importance of AMR surveillance in health systems.
The NCC should include a committee of multi-sectoral stake-
holders to support a One Health approach at national and 
international levels. This committee could be, or could develop 
from, the national working group on AMR as established by GARP, 
or the committee responsible for the NAP. The committee should 
report to the appropriate national body, for example, the Ministry of 
Health, and, where appropriate, collaborate with a relevant external 
organisation/funder.
The roles and responsibilities of the committee should be set 
out with formal terms of reference. Membership should include 
relevant technical experts and stakeholders, although individuals 
may fulfil the remit of more than one technical brief. A typical 
committee may include the following representatives: technical 
team leader, Ministry of Health, Ministry of Agriculture, national 
public health institute, coordinating AMR laboratory, international 
stakeholders, clinical microbiologist, data manager, public health 
analyst, laboratory manager, hospital manager, adult physician, 
paediatrician, pharmacist, veterinarian, infection control manager.
The functions of the NCC include:
1.    commissioning a situational analysis of current capacity and 
sustainability for AMR surveillance
2.    national strategic planning for AMR surveillance
3.    oversight of AMR surveillance implementation at a national 
level against key performance indicators
The strategic function may be extended to include other aspects 
of tackling AMR, for example strategic oversight of infection 
prevention and control (IPC) policy, development and use of 
standardised treatment guidelines, and control of the sale of anti-
microbial agents.
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Figure 1. Example organizational structure for AMR Surveillance in low resource settings. AMR, antimicrobial resistance; QA, quality 
assurance.
The NCC should have oversight of the technical team to: monitor 
quality assurance, support capacity building through training of 
national and site level participants, determine national priorities for 
pathogens in AMR surveillance in addition to those identified as 
priority pathogens by the WHO, review the scope of AMR surveil-
lance as capacity develops, integrate a One Health approach, review 
the introduction of new technologies, support research programmes 
to use AMR surveillance platforms, collaborate with neighbouring 
countries and across international regions, and develop and expand 
regional networks.
The NCC should be headed by a named National Coordinator 
for AMR surveillance from a key stakeholder institution, such 
as the Ministry of Health, Institute of Public Health, or similar 
organisation. The National Coordinator should be supported by a 
technical team responsible for training, standardisation and quality 
assurance. Where appropriate, the technical team may be led by the 
National Coordinator.
External organizations
The NCC should collaborate with international stakeholders and 
funding bodies, such as the Fleming Fund, the US Centers for 
Disease Control and Prevention, the Institut Pasteur, the European 
Centre for Disease Prevention and Control, the Bill & Melinda 
Gates Foundation, and major non-governmental organizations 
including Médecins sans Frontières, the Global Health Security 
Agenda and the WHO.
The NCC should work with external bodies to ensure standardi-
sation, training and internal and external quality assurance of all 
processes relating to AMR surveillance across participating 
countries, for example by developing and participating in national 
and international workshops.
Site Coordinating Committee
Sentinel sites should determine and define their own organizational 
structures, and how this fits into existing hospital and laboratory 
administration systems. There should, however, be a Site Co-
ordinating Committee (SCC), with defined terms of reference, 
and which includes relevant representatives, for example 
site leader, hospital administrator, data manager, laboratory 
manager, clinical microbiologist, adult physician, paediatrician, 
infection control manager, pharmacist, veterinary practitioner, 
public health specialist.
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The site leader would be expected to have project management 
and programme implementation skills, and should report to the 
NCC. The role of the SCC, led by the site coordinator, includes:
1.    working with the national technical team to facilitate a 
situational analysis of current capacity and sustainability at 
the site
2.    planning strategic priorities at the site
3.    oversight of AMR surveillance implementation at the site 
and reporting against key indicators
The roles of the SCC are to support on-site training for AMR pro-
cedures, develop locally-adapted standard operating procedures 
(SOPs), ensure quality control measures and regular audit for all 
AMR surveillance processes, work with the national technical team 
to establish internal quality assurance assessment (and ultimately 
progress to external quality assurance assessment), ensure effective 
lines of communication are in place for feedback of AMR results 
to clinicians, feedback of summarised AMR data to local partici-
pants and stakeholders (administration, clinical, laboratory and 
data staff), and report anonymised case-level data to the National 
Coordinator in a timely manner. The strategic function of the 
SCC may be extended to include other aspects of tackling AMR, 
for example, ensuring nationally agreed infection prevention and 
control policies and treatment guidelines are being followed.
Laboratories
A coordinating AMR laboratory should be identified / established 
for AMR surveillance. This may already be in place, or may be 
developed as part of the capacity-building process. Where there 
is no capacity for a coordinating AMR laboratory, countries 
should collaborate with neighbouring countries, which may be able 
to provide this service.
Coordinating AMR laboratories should be accredited, or be 
working towards laboratory accreditation12. Their staff should 
be trained by the technical team and / or external partners to 
provide training for sentinel site laboratory staff, using a “Train 
the Trainers” approach (Supplementary File 1: Appendix A). The 
functions of the coordinating AMR laboratory are:
1)    core laboratory processes (Supplementary File 1: 
Appendix D)
2)    participation in internal quality assurance
3)    participation in external quality assurance through 
appropriate international schemes
4)    provision of a reference service for core organism / antimi-
crobial combinations as a minimum, for borderline isolates 
or isolates with unexpected or unusual resistance profiles, 
and collaboration with international centres to monitor 
emerging resistance patterns
5)    assisting sentinel site laboratories to procure equipment and 
reagents, in collaboration with the NCC
6)    maintaining a biorepository for bacterial isolates
7)    promotion of good practice (including development of 
national SOPs) to ensure standardisation and quality 
control
8)    training staff at sentinel site laboratories
9)    facilitating the development of internal quality assurance at 
sentinel site laboratories
10)   provision of external quality assurance across sentinel site 
laboratories if they do not already participate in external 
quality assurance (EQA) (for example, by testing a subset 
of isolates from the sentinel site laboratories and providing 
feedback)
Each sentinel site should have its own laboratory, or access to a 
laboratory, which is able to:
1)    provide core laboratory processes, including isolate identi-
fication, susceptibility testing and storage (Supplementary 
File 1: Appendix E)
2)    communicate AMR results (organism and susceptibilities) 
to clinicians in a timely manner to improve the care of 
individual patients
3)    refer isolates with unusual, unexpected or indeterminate 
resistance patterns to the coordinating AMR laboratory for 
further testing
4)    participate in on-site training and attend national training 
as appropriate
5)    adhere to localised SOPs with quality control checks
6)   conduct internal quality assurance procedures
7)    work with the technical team and coordinating AMR 
laboratory to develop capacity, working towards participa-
tion in EQA and gaining laboratory accreditation
Situational analysis
A situational analysis of AMR should be undertaken nationally. 
This should consider all aspects of AMR surveillance, including 
clinical sampling, laboratory procedures and data systems. 
A detailed laboratory assessment can be performed using the 
WHO’s Laboratory Assessment Tool (Supplementary File 1: 
Appendix A).
Training
To promote awareness of AMR surveillance, education and 
training should be integrated into local and national education 
programmes, across all the disciplines required for AMR surveil-
lance. These include clinical, laboratory, information technology 
and public health training (Supplementary File 1: Figure 3). 
Teaching on AMR should be introduced into formal training 
pathways, including undergraduate and postgraduate curricula 
across these disciplines. AMR awareness should also be devel-
oped through continuing professional development (training 
days, workshops) at site, regional, national, and international 
levels. Such training should incorporate e-learning options and 
specific training modules. To enhance motivation, site coordinating 
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committees should consider appointing individuals with specific 
roles to act as AMR surveillance champions in clinical (doctors, 
nurses or allied professions) including infection prevention and 
control, laboratory and data services.
Sentinel site identification
The initial situational analysis should identify potential sites for 
AMR sentinel site surveillance. Site selection should be undertaken 
by the NCC through a transparent process, with involvement of an 
external stakeholder or funder where appropriate.
The sites selected, and the network as a whole, should reflect 
relevant variations in geography, socioeconomic factors and 
demography, disease epidemiology (e.g. co-morbidities such as 
HIV) and ecology, taking into account climate, rainfall and land 
use.
Surveillance that only represents one level of healthcare (e.g. 
referral hospitals) will not adequately reflect the AMR situation of 
the country. The potential for biases include:
1)    sampling only from referral hospitals, which may have 
high numbers of patients treated with antibiotics prior 
to sampling or high numbers of cases who have failed 
first-line treatment at referring facilities
2)    sampling only from hospitals may under-represent less 
severe infections e.g. sexually-transmitted infections, 
uncomplicated urinary tract infections, community acquired 
pneumonia.
3)    sampling only from healthcare outpatient clinics will result 
in under-representation of severe or invasive infection
4)    health financing systems that require patients to pay for 
investigations will include only those who are able to afford 
investigations
AMR surveillance sampling should therefore be drawn from the 
health facilities used by the population targeted for surveillance. 
These may include referral hospitals, district hospitals and 
out-patient facilities (including primary care); some institutions 
may fulfil more than one of these functions. Facilities serving a 
population sub-group, such as private hospitals in a country where 
most hospital services are delivered through the public sector, 
should only be included if the rest of the population is already 
adequately represented.
It is anticipated that sites and settings will be identified with very 
different levels of capacity (Supplementary File 1: Box 1). At the 
initiation of AMR surveillance it is important to identify organi-
sational and leadership strengths in order to develop systems and 
technical capacity. Key factors to consider when evaluating the 
potential of individual sentinel sites are:
•    whether the site has capacity and support (from local 
management / government / populations) to connect to a 
district or national network and subsequently share data 
with international agents, including the WHO
•    whether the site will be able to contribute to the national 
network through mentoring and supporting capacity 
building at subsequent sites
•    what level of investment will be required to achieve and 
sustain core AMR surveillance participation
Once a site has been identified as a potential AMR sentinel 
surveillance site, a more detailed technical analysis should be 
performed to determine which core / extended / advanced 
(Supplementary File 1: Appendix E) activities are being performed 
to the required standards, and what investments are required to 
facilitate full participation in surveillance.
Levels of AMR surveillance
To reflect variation in capacity between countries and regions, 
core, extended and advanced functions of AMR surveillance are 
described here, with the aim of prioritising a core standard to 
ensure basic quality data (Table 1 and Table 2). When these core 
processes are functioning at acceptable standards, sentinel sites 
should consider extending their capacity to include extended, and 
/ or advanced functions, and to support other sites to develop their 
capacity.
The choice of target level of surveillance should depend on:
1.    Current in-country capacity in clinical, laboratory and data 
handling areas
2.    Start-up and ongoing costs of the proposed AMR surveil-
lance system
3.    Sustainability of the proposed AMR surveillance system
Technical components
To allow full and informative interpretation of data, effective 
AMR surveillance requires well-functioning health-systems 
that serve a defined population. Standard laboratory methods for 
pathogen identification and antimicrobial susceptibility testing are 
vital in order to understand the emergence of AMR and inform 
policy, but so too are population descriptors, healthcare utilisa-
tion patterns, and the systematic assessment and investigation of 
patients (Figure 2).
Population catchment and sampling frame. Wherever possible, 
the catchment population of the health facilities included in 
surveillance should be defined and an assessment should be made 
of the patterns of healthcare utilisation in that population. This is 
important for data interpretation: total population allows estimates 
of incidence and trends; descriptors define risk factors (socio- 
economic status, urbanisation, co-morbidity levels) for national 
models of AMR burden; access to care patterns determine whether 
the healthcare facilities included are the first point of contact, 
post-treatment, or post-clinical failure level – which will have 
different AMR prevalence. Health facility selection is an important 
part of sentinel site selection and a sentinel site laboratory should 
receive samples from both inpatient and outpatient clinic facilities, 
with costs associated with AMR surveillance covered at an institu-
tional or national level, rather than directly charged to patients.
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Figure 2. Antimicrobial resistance Surveillance process.
At the extended level, a healthcare utilisation survey would be 
appropriate, and at an advanced level the population catchment 
should be described using census data or by an enumeration 
survey. It may also be appropriate to make use of existing Health 
and Demographic Surveillance Systems (HDSS)6.
Clinical surveillance. AMR surveillance data should be inter-
preted in the context of local clinical practice. This is particularly 
relevant for low-income country settings, which use syndromic 
management approaches where patients are diagnosed clinically 
and treated empirically.
At a core level, the clinical data on the laboratory request form 
should include the clinical diagnosis selected from a list of 
syndromes. For adults this includes sepsis, severe pneumonia, acute 
diarrhoea, bacterial meningitis, severe soft tissue infection, pyelone-
phritis, sexually transmitted infections (Supplementary File 1: 
Appendix B) or other (to allow for clinical discretion). The clinical 
syndromes for children include severe diarrhoeal disease, severe 
febrile illness, meningitis, severe pneumonia and neonatal possible 
serious bacterial infection (Supplementary File 1: Appendix C).
At an extended level, clinical assessment of adults and children 
(<5 years) should be based on standardised and systematic history 
and examination with case definitions from national and 
international guidance (Supplementary File 1: Appendices B 
and C)13. At an advanced level, diagnosis should be supported by 
clinical proformas with electronic storage of these extended 
clinical data (to be electronically linked to laboratory data).
Clinical sampling for AMR surveillance should be guided by the 
syndromic diagnosis for which the patient is being treated (see 
Supplementary File 1: Appendices B and C for suggested 
outline), with additional investigations undertaken at the clinician’s 
discretion. This supports interpretation of the data to guide 
empiric therapies and reduces potential bias, which may occur if 
only clinical treatment failures or the most seriously ill patients are 
investigated.
Blood culture is the core sample for AMR surveillance, as an 
indicator of pathogens causing severe, invasive and life- 
threatening disease. It is anticipated that sentinel site laboratories 
will also process other samples, but capacity building and data 
collection should initially focus on blood cultures as a core 
function. Once blood cultures are collected and processed to 
an acceptable standard, the laboratory should be encouraged to 
focus on cerebrospinal fluid (CSF) as the next priority sample 
associated with serious disease. At the extended level, laboratories 
should also have capacity to process urine, stool and urethral / 
cervical swabs  to AMR surveillance standards.
Appropriate staff training and SOPs should be in place for all pro-
cedures including collection, transport, registration, processing 
and reporting of samples. Personal protective equipment should 
be available, and sample transport should be undertaken safely, 
securely and in a timely fashion (see Supplementary File 1: 
Appendix A for links to safety manuals and guidance documents).
Isolate identification. Specimen culture and testing for antimi-
crobial susceptibility should be done by sentinel site laboratories. 
Isolates with unusual susceptibility profiles, or of uncertain iden-
tification, should be referred to the coordinating AMR laboratory, 
as well as a proportion of all isolates for quality control 
purposes. All isolates from blood or CSF specimens should be 
sent to the coordinating AMR laboratory for storage.
Reporting for AMR surveillance should focus on the eight 
WHO priority pathogens as described in the GLASS manual 
(Escherichia coli, Klebsiella pneumoniae, Acinetobacter 
baumannii, Staphylococcus aureus, Streptococcus pneumoniae, 
Salmonella spp., Shigella spp. and Neisseria gonorrhoeae) and 
other pathogens of local or national importance.
At core level, pathogen identification should be done by using rel-
evant biochemical and / or serological tests (Supplementary File 1: 
Appendix F). At the advanced level, laboratories may use molecular 
methods and automated systems such as MALDI-TOF, Vitek or 
Microscan (Supplementary File 1: Appendix E).
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Antimicrobial susceptibility testing. AMR surveillance 
programmes should include, but should not be limited to, the 
following bacteria-antimicrobial drug combinations in compliance 
with the GLASS manual (see Supplementary File 1: Appendix G 
for all combinations)14:
•    Escherichia coli vs. 3rd generation cephalosporins and 
fluoroquinolones;
•    Klebsiella pneumoniae vs. 3rd generation cephalosporins 
and carbapenems;
•    Staphylococcus aureus vs. oxacillin or cefoxitin;
•    Streptococcus pneumoniae vs. penicillin or oxacillin;
•    Salmonella species vs. fluoroquinolones;
•    Shigella species vs. fluoroquinolones;
•    Neisseria gonorrhoeae vs. 3rd generation cephalosporins
Antimicrobial susceptibility testing for priority pathogens 
should be carried out in line with international standards, pref-
erably according to the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) methodology and guidance 
(www.eucast.org). Where Clinical and Laboratory Standards 
Institute (CLSI) guidelines are used, these may also be reported. 
Unless automated systems are already in place, antimicrobial 
susceptibility testing at the core level should be performed using 
the disc diffusion method. Where additional drugs are included 
(for example Acinetobacter baumannii vs. carbapenems), they 
should be tested according to accepted guidelines (e.g. CLSI, 
EUCAST).
Sentinel site laboratories should document whether isolates 
are susceptible, intermediate or resistant (S/I/R) according to 
clinical breakpoints defined by EUCAST or CLSI. Zone sizes 
(mm) should also be measured and recorded, to allow for retro-
spective adjustment if new breakpoints are set. At the extended 
and advanced levels, minimum inhibitory concentrations (MICs) 
may be determined, e.g. by microbroth dilution (manual or auto-
mated) or gradient diffusion tests such as E-Tests. MIC values 
should be recorded (in case breakpoints change in the future).
Data management. Reporting results requires efficient data man-
agement at both sentinel site and national levels (Supplementary 
File 1: Figure 5). Quality control should be incorporated at every 
stage, with automated data validity checks and rules, as well 
as audit to check data consistency, completeness and accuracy. 
Confidentiality should be protected and data security measures 
should be in place (links to resources are given in Supplementary 
File 1: Appendix A).
The site coordinator should ensure individual case-level ano-
nymised data (as set out below) are submitted to the national 
coordinator with health facility data. These include the total 
number of patient episodes and the total number of samples proc-
essed in the laboratory. The site coordinator should feedback 
sentinel site data at least quarterly to healthcare administration, 
clinical and laboratory staff, to support continued engagement with 
AMR surveillance.
At core level, clinical data should be recorded in a standardised 
paper request form that accompanies the clinical sample to the 
laboratory. Sites operating at extended level will capture data 
using an electronic system. The minimum set of data required on 
the core clinical request form are: age, sex, clinical diagnosis, 
specimen type, sample date, admission date, hospital or commu-
nity source. Data fields collected at the extended level include: 
healthcare facility type (referral, district, health centre, general 
clinic, and STI clinic), admission ward, initial antimicrobial 
treatment and clinical diagnosis (with specific clinical signs and 
symptoms recorded at an advanced level). At core level, clinical 
and laboratory data should be linked through use of a single paper 
form on two sides of the same piece of paper – and can be entered 
(double entered to avoid transcription errors) electronically 
for onward transmission, at the end of the processing. Unique 
specimen numbers should be assigned to each sample, as well as a 
unique alphanumeric identifier for the patient episode.
Laboratories should routinely keep records of and report all 
investigations carried out, including those that are negative. For 
surveillance purposes, only the first isolate for each patient (per 
quarter) should be included for AMR surveillance reporting. 
Systematic reporting of data is important to reduce the bias that 
arises if resistant organisms are over-reported, or reported only if 
resistant to certain antibiotics.
Sites operating at extended level will capture laboratory data 
in an integrated electronic system such as WHONET (see link 
provided in Supplementary File 1: Appendix A). Clinical and 
laboratory data should be linked through the unique specimen 
identification number. WHONET has been developed to facilitate 
AMR surveillance reporting: but other systems can be used and 
data specification for aggregated data upload to the GLASS IT 
platform is available.
Use of innovative technologies and mobile communications. 
In high-income settings, innovative technologies for diagnos-
tics, therapeutics and data management are integrated into most 
health systems, with funding streams for research and executive 
bodies to evaluate and approve new technologies. In low-income 
countries, WHO and other bodies provide support for the 
implementation of new technologies, and these should be con-
sidered by countries developing AMR surveillance14. Examples 
of innovative technologies relevant to laboratory diagnostics under 
assessment include15:
•     mobile phone systems for sending microscope images – this 
could be extended to use of smartphones to share or assess 
images of disc diffusion assays to confirm zone size
•     use of electronic health records
•     nucleic acid amplification for TB diagnostics – these 
technologies could be developed to allow identification 
of resistance by genetic rather than culture methods, with 
options for cloud-based reporting
•     solar-powered autoclaves
•     freeze-drying bacterial isolates for storage (vs freezing 
at -80°C)
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Monitoring, evaluation and development
Quality assurance. Quality assurance (QA) should be led by the 
national coordinator and technical team in country, in conjunction 
with external organizations as appropriate. At a core level, all site 
procedures should be undertaken according to SOPs, adapted from 
national SOPs, and based on these guidelines. Alongside these, 
quality control (QC) and QA procedures should be established to 
ensure that the data produced are accurate and reliable.
In a clinical setting, standardisation and investigation should be 
assessed through standard quality control procedures, ensuring 
completeness of the data and investigations requested through 
audit assessment and feedback. To do this, hospital level data on 
all admissions are required to assess, for example, the diagnosis of 
all patients and whether those with an infectious syndrome were 
appropriately investigated. At a core level, the quality of clinical 
sampling and the data acquired should be subject to internal 
quality assurance assessment through the national coordinator 
and technical team. At the extended level, external assessment 
would be expected through an independent monitor.
Laboratory QA involves in-house quality control procedures, and 
internal QA and external QA (EQA) assessment. QA measures 
include specimen collection and transportation (e.g. transport 
times, specimen quality); the performance of test procedures, 
reagents, disks used, media, instruments, and personnel, and 
test results and documentation. EQA is a system for validating 
laboratory performance using an external, objective agency. EQA 
is essential for accredited laboratories and, where possible, all 
laboratories should participate in a formal EQA scheme for all tests 
performed. Traditional proficiency testing is considered to be the 
most cost-effective and useful EQA method. This involves regular 
(at least annual) dispatch of test isolates to laboratories, to be 
processed using the normal testing methods by staff who routinely 
handle such samples. Results are submitted to a central agency, 
which provides feedback and allows comparison with results 
from other laboratories (schemes listed in Supplementary File 1: 
Appendix A). If participation in formal proficiency testing is 
not possible, adequate EQA may achieved through a combina-
tion of within country retesting / rechecking and internal quality 
assurance and control procedures, with periodic external obser-
vation of practices and procedures by qualified personnel. This 
function could be provided by the coordinating AMR laboratory. 
All laboratories should be engaged in quality improvement (e.g. 
using the WHO Laboratory Assessment Tool), and should be 
encouraged to work towards full accreditation (e.g. WHO Step-
wise Laboratory Improvement Process Towards Accreditation in 
the African Region (SLIPTA); see links provided in Supplementary 
File 1: Appendix A).
Data systems and data management processes should include stand-
ard QC measures as described. They should also be subject to inter-
nal and external quality assessment by the National Coordinator 
and Technical Team (internal) and an external monitor. Evaluation 
should be through comparison of the data system description, the 
data dictionary and the data report from each site with those from 
other sentinel sites and other country systems.
Key Performance Indicators
Key Performance Indicators (KPIs) are used to monitor progress 
and identify sentinel sites where problems are arising and more 
detailed investigation is needed to understand why the indicators 
are not being met. The purpose of this investigation is to support 
sentinel sites to achieve the KPIs. GLASS is developing a moni-
toring framework for AMR surveillance and provides a sample 
framework for national KPIs (see Supplementary File 1: Appendix A 
for link). In-country indicators should be agreed at the inception of 
AMR surveillance and reviewed annually by the NCC.
Sites will vary in terms of population, geography, and health care 
facility. However, the criteria given in Supplementary File 1: 
Box 2 illustrate examples of the criteria that a well-functioning 
AMR surveillance site would be expected to meet.
Conclusions
Development of AMR surveillance is essential to address the 
global challenge of DRI. It is expected that, in line with GLASS, 
AMR surveillance systems will develop in low-income countries to 
extend AMR surveillance progressively beyond what is described 
here, to include agriculture (including animal health) and the 
environment in a One Health approach. These activities were 
beyond the scope of this work, and are normally conducted by 
parallel laboratory systems; however, they should be considered 
by NCCs as the capacity for AMR surveillance in clinical settings 
advances. Further work is also needed to interpret microbiologi-
cal data in the context of antibiotic consumption data. This could 
be done with aggregate data from national wholesale data, or 
using point prevalence surveys of antimicrobial prescriptions by 
indication (clinical syndromes), at repeated intervals, for example 
six-monthly.
The outputs of AMR surveillance must be used to underpin public 
health policy, locally, nationally and internationally. In addition, 
where possible, surveillance systems should provide a platform to 
answer research questions with local, national and international 
collaborations, which will inform our understanding of the 
emergence and evolution of AMR and, in the long term, support 
development of urgently-needed intervention strategies.
Author contributions
The work was conceived and planned by Anna C Seale, Nicola C 
Gordon, Sharon J Peacock and J Anthony G Scott. The first draft 
was written by Anna C Seale, Nicola C Gordon, Jasmin Islam and 
J Anthony G Scott, and re-written with feedback and contributions 
from all authors and an expert working group, which met on 6th/7th 
June 2016 in London, UK.
Competing interests
No competing interests were disclosed.
Grant information
This work was funded by the Fleming Fund through the Department 
of Health, UK. It was also supported by work commissioned by 
the Wellcome Trust (202959) and funded by Department of Health, 
Page 12 of 17
Wellcome Open Research 2017, 2:92 Last updated: 18 OCT 2017
UK. Anthony Scott and Anna Seale are funded by The Wellcome 
Trust (098532, 205184, respectively).
Acknowledgements
We would like to thank and acknowledge Charles Penn and 
Sophie Taysom from the Fleming Fund team and those who 
attended the expert meeting on 6th/7th June 2016 at the Well-
come Trust, London, UK: Samir Saha, Paul Turner, Rogier Van 
Doorn, Sam Kariuki, Nick Feasey, Ashika Singh-Moodley, Didem 
Torumkuney, Tim Peto, Bich-Tram Huynh, Kendall Krause, Li 
Yang Hsu, Sergey Eremin, Neil Woodford, Nan Shetty, Nienke 
van de Sande-Bruinsma and Malin Grape. We would also like to 
thank the following for their written input to the draft guideline: 
Mark Woolhouse, Anne von Gottberg, John A Crump, Chris Parry, 
Mike Sharland, Nicola Watt, Anders Tegnell, Keith Klugman and 
Scott Dowell.
Supplementary material
Supplementary File 1: A fully formatted report with all Tables and Figures and Appendices entitled “AMR Surveillance in low- and middle-
income settings. A Roadmap for Participation in the Global Antimicrobial Surveillance System (GLASS).”
Click here to access the data.
References
1. O'Neill J: Antimicrobial Resistance: Tackling a crisis for the health and wealth 
of nations. 2014; (accessed 6.6.16).  
Reference Source
2. O'Neill J: Tackling Drug-resistant Infections Globally: Final Report and 
Recommendations. 2016; (accessed 6.6.16).  
Reference Source
3. World Health Organization: Global Action Plan on Antimicrobial Resistance. 
2015; (accessed 6.6.16).  
Reference Source
4. Horton R: Stumbling around in the dark. Lancet. 2005; 365(9476): 1983.  
PubMed Abstract | Publisher Full Text 
5. World Health Organization: Global Antimicrobial Resistance Surveillance 
System: manual for early implementation. 2015; (accessed 6.6.16).  
Reference Source
6. Grundmann H, Klugman KP, Walsh T, et al.: A framework for global surveillance 
of antibiotic resistance. Drug Resist Updat. 2011; 14(2): 79–87.  
PubMed Abstract | Publisher Full Text 
7. Seale, Hutchison, et al.: Supporting surveillance capacity for antimicrobial 
resistance: Laboratory capacity strengthening for drug resistant infections in 
low and middle income countries [version 1; referees: awaiting peer review]. 
Wellcome Open Res. 2017.  
Publisher Full Text
8. Nsubuga P, White ME, Thacker SB, et al.: Public Health Surveillance: A Tool for 
Targeting and Monitoring Interventions. In: Jamison DT, Breman JG, Measham 
AR, et al., eds. Disease Control Priorities in Developing Countries. 2nd ed. 
Washington (DC); 2006.  
PubMed Abstract 
9. Lee LM, Heilig CM, White A: Ethical justification for conducting public health 
surveillance without patient consent. Am J Public Health. 2012; 102(1): 38–44. 
PubMed Abstract | Publisher Full Text | Free Full Text 
10. World Health Organization: Antimicrobial resistance: global report on 
surveillance. 2014; (accessed 05.05.16).  
Reference Source
11. Sane J, Edelstein M: Overcoming Barriers to Data Sharing in Public Health: A 
Global Perspective. 2015; (accessed 27.06.2016).  
Reference Source
12. World Health Organization: WHO Guide for the Stepwise Laboratory 
Improvement Process Towards Accreditation in the African Region (SLIPTA). 
2015; (accessed 6.6.16).  
Reference Source
13. World Health Organisation: Pocket Book of Hospital Care for Children. Problems 
of the Neonate and Young Infant. Second Edition ed, 2013; 45–69.  
Reference Source
14. Global Health Technologies Coalition: Advancing research and development to 
address poverty-related and neglected diseases and conditions. 2014.  
Reference Source
15. World Health Organization: Innovative Technologies that Address Global Health 
Concerns: Outcome of the Call Global Initiative on Health Technologies. 2010; 
(accessed 6.6.16).  
Reference Source
Page 13 of 17
Wellcome Open Research 2017, 2:92 Last updated: 18 OCT 2017
 Open Peer Review
   Current Referee Status:
Version 1
 16 October 2017Referee Report
doi:10.21956/wellcomeopenres.13565.r26408
  ,     Ben Amos Cyril Buhler
 Mott MacDonald, London, UK
 ORDiagnostics, Paris, France
This article by Anna Seale   and the accompanying roadmap offers a comprehensive framework toet al.
build a national human health AMR surveillance system. It is clearly presented and is a very helpful guide
for the many low and middle income countries that are setting up surveillance systems at present. The
Fleming Fund, which sponsored this study, is using the roadmap in discussions for support to
countries. There is a need for similar help in other areas of the surveillance of antimicrobial resistance in
animals and the environment, antimicrobial use, and in linking all these areas together as a one health
approach. 
The roadmap proposes a sentinel site system at three levels core, extended and advanced. The core
level is intended to be the minimum acceptable standard and setting this standard is very helpful. The
extended and advanced levels give suggestions for how to improve the quality of the surveillance. As
many of these suggestions can be implemented individually the authors should consider
representing these as a progression in each area rather than as discrete levels. For example surveillance
systems may choose to use software such as WHONET for entry and analysis of
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The choice of blood culture as the starting point for surveillance is understandable due to the seriousness
of sepsis. Blood culture is not however the easiest sample type to begin with from both clinical and
laboratory perspectives. It is expensive and technically challenging, the rate of positivity is often low. The
authors should consider to recommend that countries also start with one or more other sample type at
core level. Both urine and stool are easier and cheaper to deal with and have a limited range of reportable
species within GLASS. Surveillance of these would produce useful data much faster than blood culture. 
The value of linking surveillance with research could be further emphasised. Many countries have
proficient research organisations that are eager to be involved and have existing capabilities and
equipment (for example next gen sequencers) that can be used to enhance the usefullness of the
surveillance data. Some countries will choose to run surveillance at site with existing capacity such as
demographic surveillance which are general run by research groups. Linkage with academic
institutions will also be useful in encouraging full exploration and use of the data that comes out of the
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AMR surveillance system.
The publication is of excellent value to guide countries on implementation steps for AMR surveillance
and gives a good summary of the necessary steps and bodies needed for successful implementation.
Based on my experience in coordinating WHO surveillance systems for bacterial pathogens, bacterial
capacities in many developing countries are limited and often antibiotic use prohibits bacterial culture and
interferes with the right clinical treatment. I encourage the authors to highlight importance that MOH and
surveillance coordinators for AMR to align efforts with existing long standing surveillance systems and
reinforce collaboration with the sentinel sites surveillance and reference laboratories for other bacterial
networks at both country and regional levels in a an integrated rather than vertical approaches to
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Estimation of costing of surveillance activities described at country level would be an asset to help
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Estimation of costing of surveillance activities described at country level would be an asset to help
countries while developing of national action plan. Reference to donors who will be willing to support the
work especially in low income countries would also help.
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This is a well written article. The proposed conceptual frame work for monitoring AMR in Low and
Middle-Income Countries (LMIC) is comprehensive and detailed. There are however, a few fundamental
issues that should be considered to improve the quality of data, host country compliance and benefit, and
sustainability of the programme. 
In most LMIC settings, there is unrestricted use and access to a broad range of antibiotics. The
unrestricted use is largely driven by the absence of microbiology diagnostic laboratories both at
Government and public health facilities. At these locations access cannot be ethically restricted if
health care facilities are not equipped with microbiology diagnostic laboratories with trained
personnel to provide quality diagnostic services at affordable cost to the general population.
Provision of such facilities will effectively guide and restrict antibiotic use and enhance the quality
of AMR surveillance data. Thus, the approach to implementing effective surveillance for AMR in
LMIC settings need to be 3-pronged:
a) Strengthening microbiology diagnostic services at all tiers of both private and Government run
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a) Strengthening microbiology diagnostic services at all tiers of both private and Government run
health care services
b) Use of laboratory data to guide and restrict antibiotic use
c)Creating effective and sustainable AMR surveillance.
 
Since ultimately the goal of setting up AMR surveillance includes monitoring the economic impact,
it is important to actively incorporate plans for monitoring clinical outcomes in any framework for
LMIC settings. At most locations, it is not customary to return to a health care facility after an acute
illness, and record keeping is often less than optimal, thus acquisition of clinical outcome data may
warrant a proactive plan with home visits or an outreach team that is based in the community for
early, intermediate or late outcomes. 
 
A key component of AMR surveillance is timely dissemination of surveillance data to relevant
stakeholders. The programme should include plans to extend timely dissemination of surveillance
data beyond scientific and medical community to include the general public, policy-makers and
governments. This will be crucial to raising the levels of awareness of AMR and local ownership in
order to ensure sustainability of the programme in LMICs.
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